相关实验视频
Updated: May 23, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.2K
药物治疗与全球的内部 帕金森病的深度大脑刺激与深度学习的手指敲击的视频分析
Grace Yoojin Lee1, Hee Yeon Kwon1, Kanggil Park2
1Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
Scientific reports
|May 20, 2025
概括
与药物治疗相比,针对内球 (GPi) 的深度大脑刺激 (DBS) 在帕金森病 (PD) 患者中显著改善了速度和加速. GPi DBS可能与药物不同地影响精细运动控制的神经通路.
科学领域:
- 神经学 神经学
- 生物医学工程 生物医学工程
- 运动障碍 运动障碍
背景情况:
- 晚期帕金森病 (PD) 通常需要深度大脑刺激 (DBS),当药物治疗不足时.
- 与用于运动症状的药物相比,GPi DBS的具体益处需要进一步详细研究.
研究的目的:
- 为了评估GPi DBS在改善PD患者的布拉迪基尼西亚的疗效,使用手指敲击 (FT) 任务.
- 为了比较GPi DBS和药物对运动功能参数的影响.
主要方法:
- 收集了来自四个州的87名PD患者的FT任务的556个视频:药前,药后,DBS前编程和DBS后编程.
- 利用深度学习模型将2D手动重建为3D网格,提取了21个运动参数用于布拉迪基尼西亚.
- 采用机器学习来预测FT分数和统计测试来比较运动参数.
主要成果:
- 一个机器学习模型准确地预测了FT分数 (0.70准确度),与人类专家可比.
- 与药物治疗相比,DBS表现出速度和加速参数的显著改善.
- 分析显示,GPi DBS和药物对运动控制参数有明显的影响.
结论:
- 在改善PD中勃拉迪基尼西亚的特定运动控制方面,GPi DBS比药物具有显著的优势.
- 这些发现表明,GPi DBS和药物可能通过不同的机制调节涉及精细运动控制的神经通路.
- 显然,GPi DBS更直接地影响神经通路,这些神经通路在节奏手动中控制速度.
更多相关视频
相关概念视频
Parkinson's Disease: Treatment
178
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
178
Parkinson's Disease: Overview
415
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
415

